Acadia Healthcare Reports Second Quarter 2024 Results

Rhea-AI Summary

Acadia Healthcare Company (NASDAQ: ACHC) reported strong financial results for Q2 2024. Revenue increased 8.8% to $796.0 million, with same facility revenue up 8.3%. Net income reached $78.5 million, or $0.85 per diluted share. Adjusted EBITDA grew 7.6% to $187.6 million. The company added 37 beds to existing facilities and opened a new 100-bed hospital in Arizona.

Acadia updated its 2024 guidance, projecting revenue of $3.180 to $3.225 billion and adjusted EBITDA of $735 to $765 million. The company plans to add approximately 1,200 beds in 2024 and open four additional inpatient facilities in H2. With a strong financial position and strategic growth initiatives, Acadia aims to address the increasing demand for behavioral health services across the United States.

Positive

• Revenue increased 8.8% year-over-year to $796.0 million
• Same facility revenue grew 8.3% compared to Q2 2023
• Adjusted EBITDA increased 7.6% to $187.6 million
• Added 37 beds to existing facilities and opened a new 100-bed hospital
• On track to add approximately 1,200 beds in 2024
• Strong financial position with $77.2 million in cash and $371.5 million available credit

Negative

• Closure of two facilities during the second quarter
• Revised 2024 guidance due to facility closures

Financial Analyst

Acadia Healthcare's Q2 2024 results demonstrate robust growth and operational strength in the behavioral health sector. The 8.8% year-over-year revenue increase to $796.0 million is impressive, driven by both volume growth and improved pricing. The 8.3% same facility revenue growth is particularly noteworthy, indicating strong organic performance.

The company's profitability metrics are solid, with net income of $78.5 million ($0.85 per diluted share) and adjusted EBITDA of $187.6 million (up 7.6% YoY). The adjusted EBITDA margin slightly contracted to 23.6% from 23.8% in Q2 2023, which may warrant monitoring but isn't cause for immediate concern given the growth context.

Acadia's expansion strategy is progressing well, with 37 beds added to existing facilities and a new 100-bed facility opened in Arizona. The company's goal of adding approximately 1,200 beds in 2024 demonstrates its commitment to meeting growing demand. The joint venture strategy, with 21 partnerships and 11 more hospitals in the pipeline, provides a capital-efficient growth avenue.

The company's financial position remains strong, with $77.2 million in cash and $371.5 million available under its credit facility. The net leverage ratio of 2.5x is manageable and provides flexibility for future investments.

The revised 2024 guidance, while accounting for two facility closures, still projects solid growth. However, investors should note the impact of these closures ($25 million in revenue) on the full-year outlook.

Healthcare Industry Analyst

Acadia Healthcare's Q2 2024 results underscore the persistent demand for behavioral health services in the United States. The 2.6% increase in patient days coupled with a 5.6% rise in revenue per patient day indicates both volume growth and pricing power, reflecting the sector's favorable dynamics.

The company's expansion strategy aligns well with market needs. The addition of 37 beds to existing facilities and the opening of a 100-bed de novo facility in Mesa, Arizona, demonstrate Acadia's commitment to increasing access to mental health services. The plan to add approximately 1,200 beds in 2024 is ambitious but necessary given the growing demand for behavioral health and substance use treatment.

Acadia's joint venture model, with 21 partnerships and 11 operational hospitals, is a strategic approach to expand its footprint while sharing risk and capital requirements. This model could prove particularly valuable in navigating the complex healthcare landscape and local market dynamics.

The closure of two facilities during Q2 is noteworthy. While the financial impact seems relatively small ($25 million in revenue, break-even EBITDA), it's important to monitor whether this is a one-off occurrence or indicative of broader operational challenges in certain markets.

Overall, Acadia's performance reflects the resilience and growth potential of the behavioral health sector. However, the company will need to navigate challenges such as staffing shortages and potential reimbursement pressures to maintain its growth trajectory.

Provides Updated Guidance for 2024

FRANKLIN, Tenn.--(BUSINESS WIRE)-- Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter and six months ended June 30, 2024.

Second Quarter Highlights

• Revenue totaled $796.0 million, an increase of 8.8% over the second quarter of 2023
• Same facility revenue increased 8.3% compared with the second quarter of 2023, including an increase in revenue per patient day of 5.6% and an increase in patient days of 2.6%
• Net income attributable to Acadia totaled $78.5 million, or $0.85 per diluted share
• Adjusted income attributable to Acadia totaled $83.6 million, or $0.91 per diluted share
• Adjusted EBITDA totaled $187.6 million, an increase of 7.6% over the second quarter of 2023
• Continued progress on the execution of the Company’s growth strategy, including the addition of 37 beds to the Company’s existing facilities and the opening of a 100-bed de novo facility in Mesa, Arizona.

Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.

Second Quarter Results

Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, “Acadia delivered another strong financial and operating performance for the second quarter of 2024. With solid execution of our strategy, we achieved top line revenue growth of 8.8% and Adjusted EBITDA growth of 7.6% compared with the second quarter of 2023. These results reflect continued strong demand across our business, and we remain on track to add approximately 1,200 beds in 2024 to meet the growing need for our services. Looking forward, we expect the second half to benefit from further volume growth as the facilities and beds added over the past several quarters continue to ramp.”

“We commend our dedicated employees and clinicians across our facilities who continue to provide safe, high-quality care for the growing number of patients seeking help with behavioral health and substance use issues. With service lines across the continuum of care, strong clinical quality, and a focused operating model, we are well-positioned to continue to lead the behavioral health industry and address these critical needs across the United States.”

Strategic Investments for Long-Term Growth

During the second quarter of 2024, the Company continued to advance its growth strategy. This includes the addition of 37 beds to existing facilities during the quarter, and the opening of a new 100-bed acute care hospital, Agave Ridge Behavioral Hospital, in Mesa, Arizona.

For the full year, the Company remains on track to add approximately 1,200 beds, including over 400 new beds to existing facilities, and add up to 14 new Comprehensive Treatment Centers (CTCs).

The Company expects to open four additional inpatient facilities in the second half of 2024, including two new joint venture facilities. Acadia has 21 joint venture partnerships for 22 hospitals, with 11 hospitals already in operation and 11 additional hospitals expected to open in the coming years.

Cash and Liquidity

Acadia has continued to maintain a strong financial position with sufficient capital to make strategic investments in its business. As of June 30, 2024, the Company had $77.2 million in cash and cash equivalents and $371.5 million available under its $600 million revolving credit facility with a net leverage ratio of approximately 2.5x.

Net leverage ratio is a non-GAAP financial measure. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.

2024 Financial Guidance

Acadia today revised its previously announced financial guidance for 2024. Revised guidance reflects the closure of two facilities during the second quarter⁽²⁾.

	2024 Guidance Range
Revenue (1)	$3.180 to $3.225 billion
Adjusted EBITDA (1)	$735 to $765 million
Adjusted earnings per diluted share (1)	$3.45 to $3.65
Interest expense	$110 to $120 million
Tax rate	24.5% to 25.5%
Depreciation and amortization expense	$150 to $160 million
Stock compensation expense	$40 to $45 million
Operating cash flows	$525 to $575 million
Expansion capital expenditures	$425 to $475 million
Maintenance and IT capital expenditures	$90 to $110 million
Total bed additions, excluding acquisitions	Approx. 1,200 beds

(1)		Includes one-time state payments of approximately $10 million (or $0.09 per diluted share) for the year, of which approximately $7 million (or $0.06 per diluted share) was received in the first quarter of 2024.
(2)		Prior full-year guidance assumed approximately $25 million of revenue and approximately break-even EBITDA from two facilities that were closed during the second quarter.

The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.

Conference Call

Acadia will hold a conference call to discuss its second quarter financial results at 8:00 a.m. Central/9:00 a.m. Eastern Time on Thursday, August 1, 2024. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of June 30, 2024, Acadia operated a network of 258 behavioral healthcare facilities with approximately 11,400 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2024				2023				2024				2023
		(In thousands, except per share amounts)
Revenue		$	796,040			$	731,337			$	1,564,091			$	1,435,604
Salaries, wages and benefits (including equity-based compensation expense of $8,869, $7,348, $17,547 and $14,977, respectively)			419,757				386,633				837,280				777,810
Professional fees			48,050				43,803				93,738				84,928
Supplies			27,878				26,144				54,530				52,165
Rents and leases			11,889				11,725				23,752				23,149
Other operating expenses			109,690				95,912				210,763				186,750
Depreciation and amortization			36,066				32,012				72,413				63,581
Interest expense, net			29,159				20,910				56,373				40,909
Loss on impairment			1,000				8,694				1,000				8,694
Transaction, legal and other costs			6,091				9,074				8,938				15,545
Total expenses			689,580				634,907				1,358,787				1,253,531
Income before income taxes			106,460				96,430				205,304				182,073
Provision for income taxes			25,643				22,881				45,717				41,966
Net income			80,817				73,549				159,587				140,107
Net income attributable to noncontrolling interests			(2,335	)			(1,250	)			(4,722	)			(1,793	)
Net income attributable to Acadia Healthcare Company, Inc.		$	78,482			$	72,299			$	154,865			$	138,314
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic		$	0.86			$	0.79			$	1.69			$	1.53
Diluted		$	0.85			$	0.79			$	1.68			$	1.51
Weighted-average shares outstanding:
Basic			91,628				91,044				91,495				90,691
Diluted			92,043				91,546				92,051				91,640

Acadia Healthcare Company, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
		June 30,			December 31,
		2024			2023
		(In thousands)
ASSETS
Current assets:
Cash and cash equivalents		$	77,167		$	100,073
Accounts receivable, net			389,374			361,451
Other current assets			178,673			134,476
Total current assets			645,214			596,000
Property and equipment, net			2,497,856			2,266,610
Goodwill			2,261,395			2,225,962
Intangible assets, net			73,348			73,278
Deferred tax assets			2,741			6,658
Operating lease right-of-use assets			123,273			117,780
Other assets			74,225			72,553
Total assets		$	5,678,052		$	5,358,841
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt		$	66,574		$	29,219
Accounts payable			159,520			156,132
Accrued salaries and benefits			134,503			141,901
Current portion of operating lease liabilities			27,010			26,268
Other accrued liabilities			158,915			532,261
Total current liabilities			546,522			885,781
Long-term debt			1,774,556			1,342,548
Deferred tax liabilities			37,031			1,931
Operating lease liabilities			104,706			100,808
Other liabilities			150,641			140,113
Total liabilities			2,613,456			2,471,181
Redeemable noncontrolling interests			111,878			105,686
Equity:
Common stock			917			913
Additional paid-in capital			2,665,215			2,649,340
Retained earnings			286,586			131,721
Total equity			2,952,718			2,781,974
Total liabilities and equity		$	5,678,052		$	5,358,841

Acadia Healthcare Company, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
		Six Months Ended June 30,
			2024				2023
		(In thousands)
Operating activities:
Net income		$	159,587			$	140,107
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization			72,413				63,581
Amortization of debt issuance costs			2,034				1,651
Equity-based compensation expense			17,547				14,977
Deferred income taxes			39,017				347
Loss on impairment			1,000				8,694
Other			(3,942	)			1,086
Change in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net			(26,114	)			(23,397	)
Other current assets			(14,182	)			(8,743	)
Other assets			842				(322	)
Accounts payable and other accrued liabilities			(399,619	)			21,518
Accrued salaries and benefits			(8,525	)			(13,889	)
Other liabilities			9,805				2,568
Net cash (used in) provided by operating activities			(150,137	)			208,178
Investing activities:
Cash paid for acquisitions, net of cash acquired			(50,722	)			—
Cash paid for capital expenditures			(296,652	)			(157,359	)
Proceeds from sale of property and equipment			10,209				621
Other			(2,933	)			(940	)
Net cash used in investing activities			(340,098	)			(157,678	)
Financing activities:
Borrowings on long-term debt			350,000				—
Borrowings on revolving credit facility			160,000				40,000
Principal payments on revolving credit facility			(15,000	)			(20,000	)
Principal payments on long-term debt			(25,605	)			(10,625	)
Payment of debt issuance costs			(1,518	)			—
Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises			(1,668	)			(45,904	)
Contributions from noncontrolling partners in joint ventures			2,970				2,516
Distributions to noncontrolling partners in joint ventures			(1,500	)			(1,983	)
Other			(350	)			20
Net cash provided by (used in) financing activities			467,329				(35,976	)
Net (decrease) increase in cash and cash equivalents			(22,906	)			14,524
Cash and cash equivalents at beginning of the period			100,073				97,649
Cash and cash equivalents at end of the period		$	77,167			$	112,173
Effect of acquisitions:
Assets acquired, excluding cash		$	55,678			$	—
Liabilities assumed			(3,456	)			—
Contingent consideration issued in connection with an acquisition			(1,500	)			—
Cash paid for acquisitions, net of cash acquired		$	50,722			$	—

Operating Statistics
(Unaudited, Revenue in thousands)
		Three Months Ended June 30,											Six Months Ended June 30,
			2024				2023			% Change				2024				2023			% Change
Same Facility Results (1)
Revenue		$	776,145			$	716,653			8.3	%		$	1,532,401			$	1,409,073			8.8	%
Patient Days			773,499				754,099			2.6	%			1,531,489				1,495,810			2.4	%
Admissions			49,091				48,727			0.7	%			97,249				97,733			-0.5	%
Average Length of Stay (2)			15.8				15.5			1.8	%			15.7				15.3			2.9	%
Revenue per Patient Day		$	1,003			$	950			5.6	%		$	1,001			$	942			6.2	%
Adjusted EBITDA margin			29.5	%			29.5	%		0 bps				29.1	%			28.5	%		60 bps
Facility Results
Revenue		$	796,040			$	731,337			8.8	%		$	1,564,091			$	1,435,604			9.0	%
Patient Days			791,673				771,955			2.6	%			1,560,351				1,526,813			2.2	%
Admissions			50,511				50,029			1.0	%			99,569				99,935			-0.4	%
Average Length of Stay (2)			15.7				15.4			1.6	%			15.7				15.3			2.6	%
Revenue per Patient Day		$	1,006			$	947			6.1	%		$	1,002			$	940			6.6	%
Adjusted EBITDA margin			28.1	%			28.6	%		-50 bps				27.8	%			27.6	%		20 bps
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services.
(2) Average length of stay is defined as patient days divided by admissions.

Acadia Healthcare Company, Inc.
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA
(Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
			2024				2023				2024				2023
		(in thousands)
Net income attributable to Acadia Healthcare Company, Inc.		$	78,482			$	72,299			$	154,865			$	138,314
Net income attributable to noncontrolling interests			2,335				1,250				4,722				1,793
Provision for income taxes			25,643				22,881				45,717				41,966
Interest expense, net			29,159				20,910				56,373				40,909
Depreciation and amortization			36,066				32,012				72,413				63,581
EBITDA			171,685				149,352				334,090				286,563
Adjustments:
Equity-based compensation expense (a)			8,869				7,348				17,547				14,977
Transaction, legal and other costs (b)			6,091				9,074				8,938				15,545
Loss on impairment (c)			1,000				8,694				1,000				8,694
Adjusted EBITDA		$	187,645			$	174,468			$	361,575			$	325,779
Adjusted EBITDA margin			23.6	%			23.9	%			23.1	%			22.7	%
See footnotes on page 10.

Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to
Adjusted Income Attributable to Acadia Healthcare Company, Inc.
(Unaudited)
		Three Months Ended June 30,						Six Months Ended June 30,
			2024			2023			2024			2023
		(in thousands, except per share amounts)
Net income attributable to Acadia Healthcare Company, Inc.		$	78,482		$	72,299		$	154,865		$	138,314
Adjustments to income:
Transaction, legal and other costs (b)			6,091			9,074			8,938			15,545
Loss on impairment (c)			1,000			8,694			1,000			8,694
Provision for income taxes			25,643			22,881			45,717			41,966
Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.			111,216			112,948			210,520			204,519
Income tax effect of adjustments to income (d)			27,643			28,271			49,654			51,191
Adjusted income attributable to Acadia Healthcare Company, Inc.		$	83,573		$	84,677		$	160,866		$	153,328
Weighted-average shares outstanding - diluted			92,043			91,546			92,051			91,640
Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share		$	0.91		$	0.92		$	1.75		$	1.67
See footnotes on page 10.

Acadia Healthcare Company, Inc.
Footnotes
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows:
• EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization.
• Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs and loss on impairment.
• Adjusted EBITDA margin: Adjusted EBITDA divided by revenue.
• Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, loss on impairment and provision for income taxes.
• Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.
• Net leverage ratio: Long-term debt (excluding $10.5 million of unamortized debt issuance costs, discount and premium) less cash and cash equivalents divided by Adjusted EBITDA for the trailing twelve months.
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses.
(a) Represents the equity-based compensation expense of Acadia.
(b) Represents transaction, legal and other costs incurred by Acadia primarily related to legal, management transition, termination, restructuring, acquisition and other similar costs.
(c) During the three months ended June 30, 2024 and 2023, we recorded non-cash impairment charges totaling $1.0 million and $8.7 million, respectively, related to the closure of certain facilities.
(d) Represents the income tax effect of adjustments to income based on tax rates of 24.9% and 25.0% for the three months ended June 30, 2024 and 2023, respectively, and 23.6% and 25.0% for the six months ended June 30, 2024 and 2023, respectively.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731606752/en/

Investor Contact:

Patrick Feeley

Senior Vice President, Investor Relations

(615) 861-6000

Source: Acadia Healthcare Company, Inc.

FAQ

What was Acadia Healthcare's revenue for Q2 2024?

Acadia Healthcare's revenue for Q2 2024 was $796.0 million, an increase of 8.8% compared to Q2 2023.

How many beds did Acadia Healthcare (ACHC) add in Q2 2024?

Acadia Healthcare added 37 beds to its existing facilities and opened a new 100-bed facility in Mesa, Arizona during Q2 2024.

What is Acadia Healthcare's (ACHC) updated revenue guidance for 2024?

Acadia Healthcare updated its 2024 revenue guidance to a range of $3.180 to $3.225 billion.

How many new inpatient facilities does Acadia Healthcare (ACHC) plan to open in the second half of 2024?

Acadia Healthcare plans to open four additional inpatient facilities in the second half of 2024, including two new joint venture facilities.